Dr Anthony Lynham


North Brisbane biomedical sector under the microscope

29 July 2016 –

This afternoon I met with representatives form the Northside’s sciences sector to contribute to the development of Queensland’s burgeoning biomedical and life sciences industry.

I was joined at The Prince Charles hospital by researchers, medical equipment company and medical finance representatives, as well as experts from the Department of State Development. We discussed the Palaszczuk Government’s recently released Biomedical and Life Sciences Roadmap discussion paper.

Today was all about getting input from the industry about how and where we can turn ideas into products and start-ups into leaders to generate jobs and business opportunities. The experts around the table talked about projects and products that were in development and concrete steps to help move from research to commercial outcomes that can inturn help create jobs.

It was great to be surrounded by so many passionate people with so much experience.

We have a robust research sector, and existing strengths in a range of areas, including genetic/genomic services, bio fabrication, early phase clinical trials, and manufacturing of niche pharmaceutical products, medical devices and diagnostics.

The industry is forecast to grow by about four per cent in coming years and was rated fifth in the world for its biotechnology innovation potential.

The latest figures show the biomedical industry in Queensland has a total annual income of $2.7 billion. the therapeutic medicines and devices sub sector alone employs more than 6,000 people in Queensland.

To view the discussion paper and make a submission visit www.statedevelopment.qld.gov.au/biomedical

Photo above left to right: Sue Coke, Dept State Development, James Macnaughtan, Cook Medical, Assoc Prof Dan Chambers, Prince Charles Hospital, Mario Pennisi, Life Sciences Queensland, Denise Johnston, Dept State Development, Dr Shaun Gregory, Griffith University, Nagaraj Gopisetty, Translational Research Institute, and Michael Molinair, Brandon Capital.